Vaxart Has 3 Advantages Over Pfizer and Moderna

Vaxart Has 3 Advantages Over Pfizer and Moderna

Things were looking gloomy for Vaxart (NASDAQ: VXRT) a few months ago. The clinical-stage biotech company reported that its COVID-19 vaccine candidate didn't produce neutralizing antibodies in a phase 1 trial. As a result, Vaxart's shares tumbled 58% in one trading session.